Conjugation of Palbociclib with MHI-148 Has an Increased Cytotoxic Effect for Breast Cancer Cells and an Altered Mechanism of Action

The CDK4/6 inhibitor palbociclib, combined with endocrine therapy, has been shown to be effective in postmenopausal women with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. However, palbociclib is not as effective in the highly aggressive, triple-negative breast can...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Peter Jaein, Tomek, Petr, Tercel, Moana, Reynisson, Jóhannes, Park, Thomas In Hyeup, Cooper, Elizabeth Alexandra, Denny, William Alexander, Jose, Jiney, Leung, Euphemia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840619/
https://www.ncbi.nlm.nih.gov/pubmed/35164144
http://dx.doi.org/10.3390/molecules27030880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840619/
https://www.ncbi.nlm.nih.gov/pubmed/35164144
http://dx.doi.org/10.3390/molecules27030880

Ejemplares similares